# Cholesterol Test Market

> Cholesterol Test Market Research Report Information By Product Type (Test Kits and Test Strips), By Test Type (Total Cholesterol Test, High-Density Lipoprotein (HDL) Cholesterol, Low-Density Lipoprotein (LDL) and Cholesterol and Triglycerides/VLDL Cholesterol Test), By Distribution Channel (Over the Counter, and Prescription Based), By End-User (Hospitals & Clinics, Homecare and Diagnostic Centers), and By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 8.32%
- **2024:** $ 7.26 Billion
- **2025:** $ 7.86 Billion
- **2035:** $ 17.48 Billion
- **Key Players:** Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Bayer AG (DE), Danaher Corporation (US), PerkinElmer (US), Acon Laboratories (US), Quest Diagnostics (US)

**Report ID:** MRFR/HC/7266-HCR · **Pages:** 90 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** May 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/cholesterol-test-market-8738

---

## Market Summary

## **Global Cholesterol Test Market Overview**

As per MRFR analysis, the Cholesterol Test Market Size was estimated at 7.26 (USD Billion) in 2024. The Cholesterol Test Market Industry is expected to grow from 7.86 (USD Billion) in 2025 to 16.14 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 8.32% during the forecast period (2025 - 2034). The growing prevalence of high cholesterol levels is expected to drive the growth. Rising awareness about a routine screening of cholesterol levels is another significant growth driver. These are just a few of the market drivers that are driving the market. 

Source Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

## **Cholesterol Test Market Trends**

### **Prevalence of cardiovascular diseases and rising cases of obesity propel market growth**

The prevalence of cardiovascular diseases and rising cases of obesity are significantly driving market growth. Moreover, the inelastic need is related to cardiovascular patients requiring daily monitoring of Cholesterol for effective therapeutic monitoring. The health departments of various countries stipulate that children aged 9-11 should be tested, and young adults aged 17-21 should be tested. Cholesterol testing is critical to keeping patients on track with their health, as high Cholesterol shows no symptoms. Cholesterol testing involves estimating different lipids, such as triglycerides, HDL, LDL, and total blood cholesterol.

If performed effectively with proper precautions at each stage, these tests can help reduce the risk of heart attack, peripheral arterial disease, and heart disease. Thus, this factor is driving the market CAGR.

Increasing numbers of heart attacks, diabetes, kidney failure and heart attacks have affected millions worldwide. Rising R&D investments and the development of new advanced testing procedures, supported by technological advancements in healthcare infrastructure in developing countries, have increased the demand for these tests. Advances in healthcare infrastructure have facilitated a high level of efficiency in diagnostic and [Cholesterol management](../../../reports/cholesterol-management-devices-market-1045) procedures. Furthermore, the rising adoption of AI and IoT in healthcare helps boost the market over the forecast period. Thus, it is anticipated that this aspect will accelerate the Cholesterol Test market revenue globally.

## **Cholesterol Test Market Segment Insights**

### **Cholesterol Test Product Type Insights**

Based on product type, the market segments of cholesterol test includes test kits and test strips. The test kits held the majority share in 2022 in the Cholesterol Test market data. Patients now have better access to cholesterol testing thanks to the development of cutting-edge testing kits. Due to technological advancements, cholesterol testing kits are expected to be the fastest-growing segment.

### **Cholesterol Test Test Type Insights**

Based on test type, the Cholesterol Test market segmentation includes total cholesterol test, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) and Cholesterol and triglycerides/VLDL cholesterol test. The total cholesterol test dominated the market growth in 2022 and is projected to be the faster-growing segment during the forecast period, 2023-2034. This is attributed to an increased awareness of routine cholesterol testing and treatment and the sedentary lifestyle that contributes to the development of many diseases, including diabetes, which drives the market's growth.

### **Cholesterol Test Distribution Channel Insights**

The market data of cholesterol test, based on the distribution channel, include [over-the-counter](../../../reports/over-the-counter-healthcare-market-11591) and Prescription based. The target audience prefers all these distribution channels according to the consumer's requirements.

### **Cholesterol Test End-User Insights**

Based on end-user, the market data of Cholesterol Test include hospitals & clinics, home care and diagnostic centers. The diagnostic center segment dominated the market revenue of Cholesterol Test in 2022 and is projected to be the faster-growing segment during the forecast period 2023-2034. Since more and more people are being diagnosed with high total Cholesterol, the demand for the market is rising. Moreover, regular health check-ups without physician intervention are a high-impact driver for the segment's growth.

**Figure 1  Cholesterol Test Market by End-User, 2022 & 2034 (USD Billion)**

**_Source Secondary Research, Primary Research, MRFR Database and Analyst Review_**

### **Cholesterol Test Regional Insights**

By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North America Cholesterol Test market accounted for USD 2.8 billion in 2022, with a share of around 45.80%, and is expected to exhibit a significant CAGR growth during the study period. Americas is the most important regional market. Countries like the US have well-developed healthcare operations. Furthermore, one of the major reasons driving the cholesterol testing market during the forecast years is the rising prevalence of stroke in the United States.

Further, the major countries studied in the market report are The U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

**Figure 2  CHOLESTEROL TEST MARKET SHARE BY REGION 2022 (%)******

Source Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

Europe's Cholesterol Test market accounts for the second-largest market share. Rising awareness among patients regarding preventive healthcare has increased the usage of cholesterol-testing products and services. Potential players in the market have helped increase market efficiency and production of these test kits and devices, further increasing the market opportunity. Moreover, the UK market of cholesterol test held the largest market share, and the Germany market of cholesterol test was the fastest-growing market in the region.

Asia Pacific Cholesterol Test Market is expected to grow at the fastest CAGR from 2023 to 2034. Asia Pacific is growing faster and more lucrative owing to the increasing population in the region. An increase in investment and expenditure in healthcare infrastructure has led to the development of diagnostic centers and pathology laboratories for better diagnosis. Further, the China market of cholesterol test held the largest market share, and the India market of cholesterol test was the fastest-growing market in the region.

## **Cholesterol Test Key Market Players & Competitive Insights**

Major market players are spending a lot on R&D to increase their product lines, which will help the market of Cholesterol Test grow even more. Market participants are also taking various strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, mergers and acquisitions, contractual agreements, increased investments, and collaboration with other organizations. Competitors in the Cholesterol Test industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies manufacturers adopt in the Cholesterol Test industry to benefit clients and expand the market sector is manufacturing locally to reduce operating costs. The Cholesterol Test industry has provided medicine with some of the most significant benefits in recent years. The Cholesterol Test market players such as Nestle, JM Smucker Company, The Kraft Heinz Company and Starbucks Cholesterol Test Company.

Quest Diagnostics empowers people to take action to improve health outcomes. Quest's diagnostic insights, drawn from the world's largest database of clinical laboratory results, reveal new ways to identify and treat disease, inspire healthy behaviors, and improve healthcare management. In June 2022, Quest Diagnostics, the world's leading provider of diagnostic information services, announced that it would hold its 82nd. The results of six studies were presented at the American Diabetes Association Scientific Sessions in New Orleans, LA.

Also, Thermo Fisher Scientific Inc. is an American provider of scientific instruments, reagents and consumables, and software services. Thermo Fisher, headquartered in Waltham, Massachusetts, was formed in 2006 through the merger of Thermo Electron and Fisher Scientific. Thermo Fisher Scientific has acquired other reagents, consumables, instrumentation and service providers, including Life Technologies Corporation (2013), Affymetrix (2015), Affymetrix (2016), FEI Corporation (2016), BD Advanced Bioprocessing (2018), PPD (2021).

### **Key Companies in the market of Cholesterol Tests include**

- [Quest Diagnostics Incorporated](https://testdirectory.questdiagnostics.com/test/test-detail/334/cholesterol-total?cc=MASTER)
- Clinical Reference Laboratory Inc.
- Randox Laboratories Ltd.
- PTS DIAGNOSTICS
- Hoffmann-La Roche AG
- [Cell Biolabs Inc](https://www.cellbiolabs.com/hdl-and-ldlvldl-cholesterol-assay-kit).
- Laboratory Corporation of America Holdings
- Thermo Fisher Scientific
- Alere Inc.
- Eurofins Scientific

### Cholesterol Test Market Developments

- **Q2 2024: Abbott Launches Next-Generation Cholesterol Test System in the U.S.** Abbott announced the commercial launch of its new Alinity cholesterol testing system, designed to deliver faster and more accurate lipid panel results for clinical laboratories across the United States.
- **Q1 2024: Roche Receives FDA Clearance for Cobas Lipid Panel Test** Roche announced it has received U.S. FDA clearance for its Cobas Lipid Panel, a new cholesterol and triglyceride test for use on its Cobas analyzers, expanding its diagnostic portfolio in the cardiovascular space.
- **Q2 2024: Quest Diagnostics Expands Direct-to-Consumer Cholesterol Testing Service** Quest Diagnostics launched a new direct-to-consumer cholesterol test kit, allowing individuals to order and perform cholesterol tests at home, with results delivered digitally.
- **Q3 2024: Siemens Healthineers Partners with CVS Health to Offer In-Store Cholesterol Testing** Siemens Healthineers announced a partnership with CVS Health to provide point-of-care cholesterol testing in select CVS Pharmacy locations nationwide, aiming to improve access to preventive cardiovascular screening.
- **Q2 2024: Startup CardioCheck Raises $25 Million to Scale At-Home Cholesterol Monitoring Device** CardioCheck, a health tech startup, closed a $25 million Series B funding round to accelerate the commercialization of its FDA-cleared at-home cholesterol monitoring device.
- **Q1 2025: Bio-Rad Laboratories Acquires LipidSense Diagnostics for $120 Million** Bio-Rad Laboratories announced the acquisition of LipidSense Diagnostics, a company specializing in advanced cholesterol and lipid testing technologies, to strengthen its clinical diagnostics portfolio.
- **Q2 2025: FDA Approves Beckman Coulter’s New High-Sensitivity Cholesterol Assay** Beckman Coulter received FDA approval for its high-sensitivity cholesterol assay, designed to improve the detection of cardiovascular risk in routine clinical practice.
- **Q1 2024: Eurofins Scientific Opens New Cholesterol Testing Laboratory in Texas** Eurofins Scientific inaugurated a new state-of-the-art laboratory in Houston, Texas, dedicated to advanced cholesterol and lipid panel testing for clinical and research clients.
- **Q3 2024: Boston Heart Diagnostics Launches AI-Powered Cholesterol Risk Assessment Tool** Boston Heart Diagnostics introduced an AI-driven tool that integrates cholesterol test results with patient data to provide personalized cardiovascular risk assessments for clinicians.
- **Q2 2025: Roche Launches Next-Generation Point-of-Care Cholesterol Test in Europe** Roche announced the European launch of its new point-of-care cholesterol testing device, enabling rapid lipid panel results in primary care and pharmacy settings.
- **Q1 2025: Sigma-Aldrich Unveils New Reagent Kit for Automated Cholesterol Testing** Sigma-Aldrich released a new reagent kit compatible with major automated analyzers, designed to streamline cholesterol testing workflows in clinical laboratories.
- **Q3 2025: Beckman Coulter Signs Multi-Year Supply Agreement with Major U.S. Health System for Cholesterol Testing Solutions** Beckman Coulter entered into a multi-year contract to supply its cholesterol testing platforms and reagents to one of the largest health systems in the United States, expanding its footprint in hospital diagnostics.

## **Cholesterol Test Market Segmentation**

### **Cholesterol Test Product Type Outlook (USD Billion, 2018-2030)**

- Test Kits
- Test Strips

### **Cholesterol Test Test Type Outlook (USD Billion, 2018-2030)**

- Total Cholesterol Test
- High-Density Lipoprotein (HDL) Cholesterol
- Low-Density Lipoprotein (LDL)
- Cholesterol and Triglycerides/VLDL Cholesterol Test)

### **Cholesterol Test Distribution Channel Outlook (USD Billion, 2018-2030)**

- Over the Counter
- Prescription Based

### **Cholesterol Test End-User Outlook (USD Billion, 2018-2030)**

- Hospitals & Clinics
- Homecare
- Diagnostic Centers

### **Cholesterol Test Regional Outlook (USD Billion, 2018-2030)**

## Market Drivers

### Market Growth Projections

The Global Cholesterol Test Market Industry is projected to experience substantial growth over the next decade. With a market value anticipated to reach 7.26 USD Billion in 2024 and further escalate to 17.5 USD Billion by 2035, the industry is poised for a remarkable trajectory. The compound annual growth rate (CAGR) is expected to be around 8.32% from 2025 to 2035, indicating a robust expansion phase. This growth is likely driven by various factors, including technological advancements, increased health awareness, and government initiatives promoting cholesterol testing. The market's upward trend reflects a growing recognition of the importance of cholesterol management in overall health.

### Government Initiatives and Health Campaigns

Government initiatives aimed at promoting cardiovascular health play a crucial role in shaping the Global Cholesterol Test Market Industry. Various health campaigns encourage regular cholesterol screenings as part of preventive healthcare measures. These initiatives often include public awareness programs that educate individuals about the risks associated with high cholesterol levels.

By fostering a culture of regular health check-ups, governments are likely to increase the demand for cholesterol testing services. As a result, the market is expected to grow significantly, potentially reaching 17.5 USD Billion by 2035. Such proactive measures underscore the importance of cholesterol management in public health strategies.

### Rising Prevalence of Cardiovascular Diseases

The increasing incidence of cardiovascular diseases globally serves as a primary driver for the Global Cholesterol Test Market Industry. As heart-related ailments continue to rise, the demand for cholesterol testing becomes more pronounced. According to health statistics, cardiovascular diseases remain a leading cause of mortality, prompting healthcare providers to emphasize regular cholesterol screenings.

This trend is likely to escalate the market's growth, with projections indicating that the Global Cholesterol Test Market could reach 7.26 USD Billion in 2024. The heightened awareness surrounding heart health is expected to further propel the need for cholesterol testing, thereby enhancing market dynamics.

### Technological Advancements in Testing Methods

Innovations in cholesterol testing technologies significantly influence the Global Cholesterol Test Market Industry. The introduction of point-of-care testing devices and home testing kits has revolutionized how cholesterol levels are monitored. These advancements not only improve accessibility but also enhance the accuracy and speed of test results. For instance, portable devices allow patients to conduct tests in the comfort of their homes, fostering proactive health management. As these technologies become more prevalent, the market is poised for substantial growth, with an anticipated CAGR of 8.32% from 2025 to 2035. Such innovations are likely to attract a broader consumer base, further driving market expansion.

### Aging Population and Increased Health Awareness

The global demographic shift towards an aging population is a significant driver of the Global Cholesterol Test Market Industry. Older adults are generally at a higher risk for elevated cholesterol levels and related health complications. As this demographic continues to expand, the demand for cholesterol testing is expected to rise correspondingly. Moreover, increased health awareness among older adults regarding the importance of monitoring cholesterol levels contributes to this trend. This growing focus on preventive healthcare is likely to bolster market growth, with projections indicating a robust expansion trajectory in the coming years. The intersection of aging and health consciousness presents a unique opportunity for market stakeholders.

### Integration of Cholesterol Testing in Routine Health Check-ups

The integration of cholesterol testing into routine health check-ups is becoming increasingly common, thereby driving the Global Cholesterol Test Market Industry. Healthcare providers are recognizing the importance of monitoring cholesterol levels as part of comprehensive health assessments. This trend is particularly evident in primary care settings, where regular screenings are encouraged to identify potential health risks early. As more individuals undergo routine check-ups that include cholesterol testing, the market is expected to experience sustained growth. This shift towards preventive healthcare aligns with broader health trends, suggesting a favorable outlook for the industry in the coming years.

## Future Outlook

The Cholesterol Test Market is projected to grow at an 8.32% CAGR from 2025 to 2035, driven by increasing health awareness, technological advancements, and rising prevalence of cardiovascular diseases.

**New opportunities:**

- Development of portable cholesterol testing devices for home use.
- Integration of AI-driven analytics in cholesterol testing services.
- Expansion of [telehealth](https://www.marketresearchfuture.com/reports/telehealth-market-900)platforms offering cholesterol monitoring solutions.

By 2035, the market is expected to be robust, reflecting significant advancements and increased consumer engagement.

## Segment Insights

### By Test Type: Lipid Panel (Largest) vs. Triglycerides Test (Fastest-Growing)

In the Cholesterol Test Market, the segment is primarily dominated by the Lipid Panel, which accounts for a significant share due to its comprehensive assessment of cholesterol types, including LDL, HDL, and total cholesterol levels. This test is recognized as a staple in cardiovascular health monitoring, thereby driving a consistent demand. Conversely, the Triglycerides Test, although currently smaller in market share, is gaining traction thanks to increased awareness about the impact of triglycerides on heart health, resulting in a burgeoning interest among healthcare providers and patients alike.

The growth trends in this segment are largely influenced by rising health concerns related to cardiovascular diseases, leading to an increase in preventive testing. The Lipid Panel remains essential for regular screenings, whereas heightened education on the risks of high triglyceride levels is propelling the Triglycerides Test with notable speed. Technological advancements and improved diagnostic techniques also contribute to more accurate results, enhancing the credibility of these tests and promoting their adoption in routine evaluations.

Lipid Panel (Dominant) vs. Triglycerides Test (Emerging)

The Lipid Panel is a well-established component of cholesterol testing that offers a detailed breakdown of various cholesterol types and is considered the gold standard for cardiovascular risk assessment. Its dominance is attributed to its ability to provide comprehensive insights into an individual's lipid profile, facilitating informed clinical decisions. In contrast, the Triglycerides Test is emerging as a critical measure in the health landscape, particularly due to the rising recognition of triglycerides' role in heart disease. This test is gaining popularity for its simplicity and effectiveness in assessing metabolic health. Both tests play essential roles, yet the Lipid Panel remains the leading choice for healthcare providers, while the Triglycerides Test is rapidly gaining acceptance in preventive health strategies.

### By End User: Hospitals (Largest) vs. Diagnostic Laboratories (Fastest-Growing)

The Cholesterol Test Market exhibits a diverse distribution among end users, with hospitals commanding the largest share. Their extensive infrastructure and patient base facilitate a high volume of routine screenings and diagnostics. Meanwhile, diagnostic laboratories are emerging as the fastest-growing segment, driven by advancements in technology that enable rapid testing, efficient workflows, and a demand for specialized services. As awareness of cholesterol-related health concerns increases, the role of these laboratories is becoming integral to patient care.

The growth of the cholesterol testing segment is largely influenced by rising awareness regarding cardiovascular health, leading to an increase in preventive screenings. Factors such as the growing aging population, lifestyle changes, and an emphasis on early detection of health issues are propelling this market forward. Furthermore, home care settings and physician offices are also up-and-coming, providing convenient options for patients, showcasing a trend towards personalized healthcare delivery and monitoring that complements traditional healthcare models.

Hospitals (Dominant) vs. Home Care Settings (Emerging)

Hospitals remain the dominant players in the cholesterol testing market due to their capacity to perform a comprehensive range of tests and provide immediate results to patients. Equipped with advanced diagnostic tools and experienced personnel, they play a crucial role in managing patient health. On the other hand, home care settings are emerging as a significant alternative for cholesterol testing. They cater to the growing demand for at-home health monitoring, particularly among populations seeking convenience and comfort. This segment is bolstered by innovations such as portable testing kits and telehealth services, making it easier for patients to access their health information without visiting medical facilities. The combination of these two segments highlights a shift in healthcare delivery methods that prioritize accessibility and patient-centered care.

### By Age Group: Adults (Largest) vs. Elderly (Fastest-Growing)

In the Cholesterol Test Market, the distribution of market share among age groups reveals that adults constitute the largest segment, driven by the rising prevalence of lifestyle-related diseases and increasing awareness about health screening. Children, while being crucial for preventive healthcare practices, represent a smaller share of the market, reflecting the low emphasis on cholesterol testing during early years, which is often reserved for severe cases or family history indicators.

The growth trends in the cholesterol test market indicate that the elderly population is emerging as the fastest-growing segment. This can be attributed to the growing aging demographic, enhancing healthcare access, and increased emphasis on preventive health measures in older adults, who are more susceptible to cardiovascular diseases. As a result, marketing efforts are increasingly targeted towards this age group, signaling potential growth opportunities.

Adults: (Dominant) vs. Elderly (Emerging)

In the Cholesterol Test Market, adults are recognized as the dominant age group, primarily due to their higher engagement with regular health check-ups and lifestyle assessments. The prevalence of conditions such as obesity and hypertension among adults drives the demand for cholesterol testing, making it a standard practice in healthcare. Conversely, the elderly segment is emerging as a significant factor, driven by the increase in age-related health concerns and a proactive approach to healthcare. This demographic not only faces heightened health risks but also shows a growing openness towards innovative testing solutions and preventive measures. As awareness increases, the elderly population is expected to drive significant demand for cholesterol testing in the coming years.

### By Testing Method: Blood Test (Largest) vs. Point-of-Care Testing (Fastest-Growing)

In the Cholesterol Test Market, the Blood Test segment holds the largest market share, attributed to its established reliability and comprehensive results. This method has been the gold standard for cholesterol testing, appealing to both medical professionals and patients seeking accurate diagnostics. However, Point-of-Care Testing is rapidly gaining traction, effectively catering to the demand for convenience in healthcare settings, particularly in emergency and remote areas. 
The growth trends within the Testing Method segment reflect a shift towards more accessible and patient-friendly testing options. Point-of-Care Testing is emerging as a front-runner, driven by advancements in technology and the increasing emphasis on preventive healthcare. Home Testing Kits are also on the rise, capitalizing on consumer trends favoring self-management of health and wellness, which complements the growth of Point-of-Care Testing.

Testing Method: Blood Test (Dominant) vs. Home Testing Kits (Emerging)

The Blood Test segment is characterized by its robust infrastructure and extensive testing protocols, ensuring accurate cholesterol measurements that are critical for cardiovascular risk assessments. It is widely endorsed by healthcare providers, resulting in high patient trust. Conversely, Home Testing Kits are becoming an increasingly popular choice among consumers seeking convenience, enabling them to monitor their cholesterol levels in privacy and comfort. These kits are easy to use and have seen enhancements in accuracy and reliability. Although still emerging compared to traditional methods, the rise of Home Testing Kits signifies a shift towards self-directed healthcare, aligning with consumer preferences for personalized health management. This dynamic between the dominant Blood Test and the emerging Home Testing Kits illustrates the evolving landscape of cholesterol testing.

### By Frequency of Testing: Annual Screening (Largest) vs. Quarterly Monitoring (Fastest-Growing)

In the Cholesterol Test Market, the segment of Frequency of Testing reveals significant diversity in usage patterns. Annual Screening currently holds the largest market share, as it is widely recommended for general health monitoring, especially among individuals at risk for heart disease. In contrast, Biannual Screening occupies a middle ground, gaining traction among patient populations who prefer more frequent assessments without being cumbersome. Meanwhile, Quarterly Monitoring, though initially less favored, is rapidly gaining popularity, due to increased awareness and proactive health management, particularly in individuals with elevated cholesterol levels.

Cholesterol Screening: Annual Screening (Dominant) vs. Quarterly Monitoring (Emerging)

Annual Screening is recognized as the dominant player in the Frequency of Testing segment, primarily due to its established guidelines and the long-standing practice of healthcare providers. Patients often opt for annual tests as it aligns with routine health check-ups, providing comprehensive insights into their cholesterol health. On the flip side, Quarterly Monitoring is emerging as a formidable contender, supported by a growing trend toward personalized medicine and continuous health monitoring. This segment appeals particularly to those with chronic health conditions, as it facilitates timely interventions and adjustments in treatment regimens. As technology advances, the feasibility and accessibility of quarterly testing will likely further accelerate its adoption, positioning it as a critical component of proactive health management.

## Regional Market Share Analysis

### North America : Market Leader in Testing

North America continues to lead the Cholesterol Test Market, holding a significant share of 3.63 billion in 2024. The region's growth is driven by increasing awareness of cardiovascular diseases, advancements in diagnostic technologies, and supportive healthcare policies. Regulatory bodies are promoting preventive healthcare measures, which further boosts demand for cholesterol testing. The aging population and rising obesity rates are also key factors contributing to market expansion. The competitive landscape in North America is robust, featuring major players like Abbott Laboratories, Roche Diagnostics, and Thermo Fisher Scientific. These companies are investing heavily in R&D to innovate and improve testing accuracy. The U.S. is the largest market, supported by a well-established healthcare infrastructure and high healthcare expenditure. The presence of leading manufacturers ensures a steady supply of advanced testing solutions, catering to the growing demand for cholesterol testing services.

### Europe : Emerging Market Dynamics

Europe's Cholesterol Test Market is valued at 2.0 billion, reflecting a growing emphasis on preventive healthcare and early diagnosis. The region benefits from stringent regulations that ensure high-quality testing standards, driving demand for reliable cholesterol tests. Increased public health initiatives aimed at reducing cardiovascular diseases are also pivotal in shaping market dynamics. Countries like Germany and the UK are leading the charge, with rising healthcare investments and awareness campaigns. The competitive landscape in Europe is characterized by the presence of key players such as Siemens Healthineers and Bayer AG. These companies are focusing on expanding their product portfolios and enhancing testing technologies. The European market is witnessing collaborations between public health organizations and private firms to improve testing accessibility. As a result, the region is poised for steady growth, supported by a commitment to health innovation and regulatory compliance.

### Asia-Pacific : Rapid Growth Potential

The Asia-Pacific region, valued at 1.5 billion, is experiencing rapid growth in the Cholesterol Test Market, driven by increasing healthcare access and rising awareness of lifestyle diseases. Governments are implementing policies to enhance healthcare infrastructure, which is crucial for expanding testing capabilities. The growing middle class and urbanization are also contributing to higher demand for cholesterol testing services, as more individuals seek preventive health measures. Leading countries in this region include China and India, where the healthcare sector is evolving rapidly. Key players like Danaher Corporation and PerkinElmer are expanding their presence to tap into this burgeoning market. The competitive landscape is becoming increasingly dynamic, with local companies emerging alongside established global players. This growth trajectory is expected to continue as the region prioritizes health and wellness initiatives.

### Middle East and Africa : Emerging Market Opportunities

The Middle East and Africa (MEA) market for cholesterol testing is valued at 0.13 billion, reflecting emerging opportunities in healthcare. The region is witnessing a gradual increase in awareness regarding cardiovascular health, driven by rising incidences of lifestyle-related diseases. Governments are beginning to invest in healthcare infrastructure, which is essential for improving access to cholesterol testing. Regulatory frameworks are also evolving to support better health outcomes, fostering a conducive environment for market growth. Countries like South Africa and the UAE are at the forefront of this market, with increasing healthcare investments and initiatives aimed at enhancing public health. The competitive landscape includes both local and international players, with companies like Acon Laboratories making strides in the region. As healthcare access improves, the demand for cholesterol testing is expected to rise, presenting significant growth potential for stakeholders in the MEA region.

## Competitive Benchmarking

The Cholesterol Test Market is currently characterized by a dynamic competitive landscape, driven by increasing awareness of cardiovascular health and the rising prevalence of hyperlipidemia. Key players such as Abbott Laboratories (US), Roche Diagnostics (CH), and Siemens Healthineers (DE) are strategically positioned to leverage innovation and technological advancements. These companies focus on enhancing their product offerings through research and development, while also pursuing strategic partnerships to expand their market reach. The collective strategies of these firms contribute to a moderately fragmented market structure, where competition is intensified by the continuous introduction of advanced testing solutions.
In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and optimize supply chains. This approach not only enhances operational efficiency but also allows for quicker response times to market demands. The competitive structure of the market remains moderately fragmented, with several key players exerting influence through their established brand presence and innovative capabilities. The interplay between these companies shapes the overall market dynamics, fostering an environment conducive to growth and development.
In November 2025, Abbott Laboratories (US) announced the launch of a new point-of-care cholesterol testing device aimed at improving accessibility for patients in remote areas. This strategic move is significant as it aligns with the growing trend towards decentralized healthcare, enabling quicker diagnosis and treatment options for individuals who may otherwise face barriers to traditional testing facilities. The introduction of this device is likely to enhance Abbott's competitive positioning in the market.
Similarly, in October 2025, Roche Diagnostics (CH) unveiled a partnership with a leading telehealth provider to integrate cholesterol testing into virtual healthcare platforms. This collaboration is indicative of the increasing convergence of digital health and traditional diagnostics, allowing Roche to tap into a broader patient base while promoting preventive healthcare measures. The strategic importance of this partnership lies in its potential to streamline patient access to cholesterol testing, thereby fostering early intervention and management of cardiovascular risks.
In December 2025, Siemens Healthineers (DE) announced an investment in AI-driven analytics to enhance the accuracy and efficiency of cholesterol testing processes. This initiative reflects a broader trend towards the integration of artificial intelligence in healthcare diagnostics, which could significantly improve patient outcomes by enabling more precise risk assessments. The strategic focus on AI not only positions Siemens as a leader in innovation but also underscores the importance of technology in shaping the future of the Cholesterol Test Market.
As of December 2025, current competitive trends are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances among key players are reshaping the landscape, fostering collaboration that enhances product offerings and market penetration. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on innovation, technological advancements, and supply chain reliability. This shift suggests that companies that prioritize these elements will be better positioned to thrive in the evolving market.

## Recent News & Developments

- **Q2 2024: Abbott Launches Next-Generation Cholesterol Test Market System in the U.S.** Abbott announced the commercial launch of its new Alinity cholesterol testing system, designed to deliver faster and more accurate lipid panel results for clinical laboratories across the United States.
- **Q1 2024: Roche Receives FDA Clearance for Cobas Lipid Panel Test** Roche announced it has received U.S. FDA clearance for its Cobas Lipid Panel, a new cholesterol and triglyceride test for use on its Cobas analyzers, expanding its diagnostic portfolio in the cardiovascular space.
- **Q2 2024: Quest Diagnostics Expands Direct-to-Consumer Cholesterol Testing Service** Quest Diagnostics launched a new direct-to-consumer cholesterol test kit, allowing individuals to order and perform cholesterol tests at home, with results delivered digitally.
- **Q3 2024: Siemens Healthineers Partners with CVS Health to Offer In-Store Cholesterol Testing** Siemens Healthineers announced a partnership with CVS Health to provide point-of-care cholesterol testing in select CVS Pharmacy locations nationwide, aiming to improve access to preventive cardiovascular screening.
- **Q2 2024: Startup CardioCheck Raises $25 Million to Scale At-Home Cholesterol Monitoring Device** CardioCheck, a health tech startup, closed a $25 million Series B funding round to accelerate the commercialization of its FDA-cleared at-home cholesterol monitoring device.
- **Q1 2025: Bio-Rad Laboratories Acquires LipidSense Diagnostics for $120 Million** Bio-Rad Laboratories announced the acquisition of LipidSense Diagnostics, a company specializing in advanced cholesterol and lipid testing technologies, to strengthen its clinical diagnostics portfolio.
- **Q2 2025: FDA Approves Beckman Coulter’s New High-Sensitivity Cholesterol Assay** Beckman Coulter received FDA approval for its high-sensitivity cholesterol assay, designed to improve the detection of cardiovascular risk in routine clinical practice.
- **Q1 2024: Eurofins Scientific Opens New Cholesterol Testing Laboratory in Texas** Eurofins Scientific inaugurated a new state-of-the-art laboratory in Houston, Texas, dedicated to advanced cholesterol and lipid panel testing for clinical and research clients.
- **Q3 2024: Boston Heart Diagnostics Launches AI-Powered Cholesterol Risk Assessment Tool** Boston Heart Diagnostics introduced an AI-driven tool that integrates cholesterol test results with patient data to provide personalized cardiovascular risk assessments for clinicians.
- **Q2 2025: Roche Launches Next-Generation Point-of-Care Cholesterol Test Market in Europe** Roche announced the European launch of its new point-of-care cholesterol testing device, enabling rapid lipid panel results in primary care and pharmacy settings.
- **Q1 2025: Sigma-Aldrich Unveils New Reagent Kit for Automated Cholesterol Testing** Sigma-Aldrich released a new reagent kit compatible with major automated analyzers, designed to streamline cholesterol testing workflows in clinical laboratories.
- **Q3 2025: Beckman Coulter Signs Multi-Year Supply Agreement with Major U.S. Health System for Cholesterol Testing Solutions** Beckman Coulter entered into a multi-year contract to supply its cholesterol testing platforms and reagents to one of the largest health systems in the United States, expanding its footprint in hospital diagnostics.

## Report Scope

| MARKET SIZE 2024 | 7.26(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 7.86(USD Billion) |
| MARKET SIZE 2035 | 17.48(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.32% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Bayer AG (DE), Danaher Corporation (US), PerkinElmer (US), Acon Laboratories (US), Quest Diagnostics (US) |
| Segments Covered | Application, Test Type, End User, Technology |
| Key Market Opportunities | Integration of telehealth services enhances accessibility and convenience in the Cholesterol Test Market. |
| Key Market Dynamics | Rising consumer awareness drives demand for cholesterol testing, influencing market dynamics and competitive strategies. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation of the Cholesterol Test Market by 2035?**
A: The Cholesterol Test Market is projected to reach a valuation of 17.48 USD Billion by 2035.

**Q: What was the market valuation of the Cholesterol Test Market in 2024?**
A: In 2024, the Cholesterol Test Market was valued at 7.26 USD Billion.

**Q: What is the expected CAGR for the Cholesterol Test Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Cholesterol Test Market during the forecast period 2025 - 2035 is 8.32%.

**Q: Which companies are considered key players in the Cholesterol Test Market?**
A: Key players in the Cholesterol Test Market include Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, and Thermo Fisher Scientific.

**Q: What segment of the Cholesterol Test Market had the highest valuation in 2024?**
A: The Lipid Panel segment had the highest valuation in 2024, amounting to 2.91 USD Billion.

**Q: How does the market for cholesterol testing in hospitals compare to that in home care settings?**
A: In 2024, the market for cholesterol testing in hospitals was valued at 2.18 USD Billion, whereas home care settings accounted for 1.09 USD Billion.

**Q: What is the projected market size for adults in the Cholesterol Test Market by 2035?**
A: The projected market size for adults in the Cholesterol Test Market is expected to reach 9.8 USD Billion by 2035.

**Q: What testing method is anticipated to grow significantly in the Cholesterol Test Market?**
A: The Blood Test method is anticipated to grow significantly, with a projected valuation of 7.0 USD Billion by 2035.

**Q: What frequency of testing is expected to dominate the Cholesterol Test Market by 2035?**
A: Annual Screening is expected to dominate the Cholesterol Test Market, projected to reach 5.25 USD Billion by 2035.

**Q: How does the market for cholesterol testing in elderly individuals compare to that in children?**
A: In 2024, the market for cholesterol testing in elderly individuals was valued at 2.46 USD Billion, compared to 0.8 USD Billion for children.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/cholesterol-test-market-8738*